TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14764783

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone (rhGH)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11579192

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both antipsychotic medication and behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial of antipsychotic medication
Number of subjects: 0
Study: 9137223

Group type: EXPERIMENTAL
Intervention: Transradial PTCA
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Transbrachial PTCA
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Transfemoral PTCA
Number of subjects: 900
Study: 7896367

Group type: EXPERIMENTAL
Intervention: Urinary calcium-creatinine ratio (Uca/Ucr)
Number of subjects: 352
Study: 3450522

Group type: COMPARATOR
Intervention: Nitrendipine (once daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrendipine (twice daily)
Number of subjects: 22
Study: 29373235

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg per day for 3 days)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 27825313

Group type: EXPERIMENTAL
Intervention: Pharmacist medication therapy management (MTM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 47
Study: 25693889

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 120 ng/mL
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 240 ng/mL
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 180 ng/mL and 360 ng/mL
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 120 ng/mL and 240 ng/mL
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23669628

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (4 mg/day)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Low-dose folic acid (0.4 mg/day)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Population rate (Brazilian population)
Number of subjects: 268
Study: 21679353

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort® SMART®) 160/4.5 µg twice daily plus 160/4.5 µg for symptom relief
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Conventional best standard treatment (CBST)
Number of subjects: 1835
Study: 19354338

Group type: EXPERIMENTAL
Intervention: Micro-costing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gross-costing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear model (GLM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable analysis of cost
Number of subjects: 0
Study: 16713340

Group type: EXPERIMENTAL
Intervention: People with insomnia (PWI)
Number of subjects: 703

Group type: COMPARATOR
Intervention: People not having insomnia (PNI)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: African-Americans
Number of subjects: 703

Group type: COMPARATOR
Intervention: Caucasians
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Gender, age group, and season
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis
Number of subjects: 703
Study: 12890205

Group type: EXPERIMENTAL
Intervention: 20% DFO in aqueous cream
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aqueous cream alone (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20% ALA with 20% DFO
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20% ALA (Control)
Number of subjects: 18
Study: 10702175

Group type: EXPERIMENTAL
Intervention: Carotenoid supplement (25 mg total carotenoids/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of carotenoids and vitamin E (335 mg RRR-alpha-tocopherol/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8836263

Group type: EXPERIMENTAL
Intervention: High spinal intraoperative block to T4 using 6mls of 0.5% bupivacaine plus continuous epidural 0.125% bupivacaine/0.0025% diamorphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural 0.5% bupivacaine block to T4 plus continuous epidural infusion of 0.125% bupivacaine/0.0025% diamorphine
Number of subjects: 20
Study: 1290723

Group type: EXPERIMENTAL
Intervention: Sizofiran and recombinant interferon-gamma before and after SLL, followed by human lymphoblastoid interferon-alpha
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 24
Study: 6367415

Group type: EXPERIMENTAL
Intervention: Gallopamil 150 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31005162

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram based on joint T2WI and DWI
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nomogram based only on clinicopathologic risk factors
Number of subjects: 96
Study: 28341278

Group type: EXPERIMENTAL
Intervention: Kinematic alignment TKA
Number of subjects: 877

Group type: COMPARATOR
Intervention: Conventional alignment TKA
Number of subjects: 877
Study: 27301469

Group type: EXPERIMENTAL
Intervention: Sildenafil (pulmonary vasodilator)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: COMPARATOR
Intervention: Pulmonary arterial hypertension
Number of subjects: 151

Group type: COMPARATOR
Intervention: HF with preserved ejection fraction
Number of subjects: 151

Group type: COMPARATOR
Intervention: HF with reduced ejection fraction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall HF patients (n=103)
Number of subjects: 151
Study: 25126027

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive regimen (IAR) defined as ≥ 3 antihypertensives including a diuretic
Number of subjects: 284

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 284
Study: 22196033

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5mg/kg
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15mg/kg
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 827
Study: 19752011

Group type: EXPERIMENTAL
Intervention: CRT RENEWAL
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Clinical risk score from CRT RENEWAL
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Regression model and clinical risk score applied to HF-HRV study
Number of subjects: 1274
Study: 17526166

Group type: EXPERIMENTAL
Intervention: Suanzaoren Decoction (SZRD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comprehensive therapy (control group)
Number of subjects: 60
Study: 15657021

Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG) + Hypoglycemia Anticipation, Awareness and Treatment Training (HAATT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG) + HAATT
Number of subjects: 60
Study: 11220796

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 63
Study: 9734351

Group type: EXPERIMENTAL
Intervention: Children with asthma and wheezing (51 children)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Children with wheezing alone (69 children)
Number of subjects: 1388
Study: 8126510

Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl) with or without tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl)
Number of subjects: 0
Study: 3288845

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (E2V) (2 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31770329

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both intubation modes
Number of subjects: 110
Study: 31288822

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol with placebo (0.9% sodium chloride solution)
Number of subjects: 60
Study: 28492193

Group type: EXPERIMENTAL
Intervention: Live modeling intervention
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TPD technique with customized playing dental objects
Number of subjects: 98
Study: 26457059

Group type: EXPERIMENTAL
Intervention: Propranolol (1.5-2 mg/kg/day divided into three doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silver nitrate cautery
Number of subjects: 100
Study: 23591599

Group type: EXPERIMENTAL
Intervention: Vedolizumab 2, 6, or 10 mg/kg on days 1, 15, and 43, followed by maintenance dosing every 8 weeks
Number of subjects: 72
Study: 21479563

Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripter
Number of subjects: 80

Group type: COMPARATOR
Intervention: Holmium: YAG laser
Number of subjects: 80
Study: 18672764

Group type: EXPERIMENTAL
Intervention: Xinkeshu Tablet (XKS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 60
Study: 16205924

Group type: EXPERIMENTAL
Intervention: 9NC administered with food (standard meal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 9NC administered under fasting conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 9AC administered with food (standard meal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 9AC administered under fasting conditions
Number of subjects: 16
Study: 12666001

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine + 50 microg clonidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clonidine (combined with morphine)
Number of subjects: 45
Study: 10750638

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9167105

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 942

Group type: COMPARATOR
Intervention: Regular human insulin (Humulin R)
Number of subjects: 942
Study: 8242291

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 20
Study: 2953174

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.04 microgram/kg/min) in hypertensive men (n = 13)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.04 microgram/kg/min) in normotensive men (n = 12)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Infused saline in normotensive subjects (n = 12)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of venous platelets in hypertensive men (n = 35)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Plasma concentration of beta‐thromboglobulin (BTG) in hypertensive men (n = 35)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of BTG concentration in venous vs arterial blood in normotensive subjects (n = 44)
Number of subjects: 79
Study: 30612549

Group type: EXPERIMENTAL
Intervention: Weight loss intervention at the workplace
Number of subjects: 6
Study: 29480363

Group type: EXPERIMENTAL
Intervention: US + LLLT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TE + US + LLLT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26588208

Group type: EXPERIMENTAL
Intervention: Clinically infected silicone stents (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clinically noninfected silicone stents (n = 9)
Number of subjects: 19
Study: 25089313

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 56
Study: 21883302

Group type: EXPERIMENTAL
Intervention: Stable condition
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Upwardly unstable condition
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Downwardly unstable condition
Number of subjects: 76
Study: 19469799

Group type: EXPERIMENTAL
Intervention: 250 mg GTPs twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 250 mg GTPs
Number of subjects: 56
Study: 17366092

Group type: EXPERIMENTAL
Intervention: Counselling by a social worker focused on motivation, goal setting, and planning of return to work.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard case management offered by municipalities (Control group).
Number of subjects: 264
Study: 12655904

Group type: EXPERIMENTAL
Intervention: Parenting program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 44
Study: 10927051

Group type: EXPERIMENTAL
Intervention: Experimental treatment (effectiveness of 2.0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant-sequence design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating-sequence design
Number of subjects: 0
Study: 9574145

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8268525

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg administered just before and after CPB, and every 90 minutes during CPB)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 157
Study: 2421015

Group type: EXPERIMENTAL
Intervention: Ultrasound-directed transperineal needle biopsy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional transperineal biopsy
Number of subjects: 55
Study: 30747489

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral drug-coated balloon (DCB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty (PTA)
Number of subjects: 100
Study: 28032813

Group type: EXPERIMENTAL
Intervention: Circle of Life (COL) program
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635
Study: 27335282

Group type: EXPERIMENTAL
Intervention: Cycle exercise at 50% peak oxygen uptake in the heat (37°C and 50% RH) in the morning (0600)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cycle exercise at 50% peak oxygen uptake in the heat (37°C and 50% RH) in the evening (1800)
Number of subjects: 19
Study: 25398294

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 30

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 30
Study: 22381987

Group type: EXPERIMENTAL
Intervention: Computerized insulin dose calculator
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (paper protocol)
Number of subjects: 300
Study: 20153761

Group type: EXPERIMENTAL
Intervention: Size judgement task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animateness judgement task
Number of subjects: 0
Study: 18325458

Group type: EXPERIMENTAL
Intervention: Telemedicine (T) plus usual care (UC)
Number of subjects: 48
Study: 15988130

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (matched for gender, age, and smoking habits)
Number of subjects: 31
Study: 14582102

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg intravenously
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study: 10478579

Group type: EXPERIMENTAL
Intervention: Nocturnal continuous subcutaneous apomorphine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion with normal saline
Number of subjects: 8
Study: 8734765

Group type: EXPERIMENTAL
Intervention: Familial hemiplegic migraine linked to chromosome 19
Number of subjects: 66

Group type: COMPARATOR
Intervention: Familial hemiplegic migraine not linked to chromosome 19
Number of subjects: 66
Study: 1878231

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6311306

Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg orally three times a day, starting the day before cis-platinum and ending the day after)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorpromazine (12.5 mg IM, 15 minutes before cis-platinum)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nabilone and Chlorpromazine
Number of subjects: 20
Study: 30404544

Group type: EXPERIMENTAL
Intervention: Topical product based on 0.8% piroxicam and 50+ solar filters (ACTX), applied twice a day after C-PDT or DL-PDT.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard Sunscreens (SS group) with SPF50+ or SPF100+ associated with photolyase.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ACTX
Number of subjects: 68

Group type: COMPARATOR
Intervention: SS group
Number of subjects: 68
Study: 28272290

Group type: COMPARATOR
Intervention: Continuous interscalene block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous supraclavicular block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous suprascapular block
Number of subjects: 75
Study: 25017941

Group type: EXPERIMENTAL
Intervention: Weight Restoration (WR) hospitalization
Number of subjects: 82

Group type: COMPARATOR
Intervention: Medical Stabilization (MS) hospitalization
Number of subjects: 82
Study: 25259704

Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 2962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: TDF, FTC/TDF, Placebo
Number of subjects: 2962
Study: 21813629

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg at induction followed by 0.3 mg/kg/h infusion)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (normal saline equivalent volume)
Number of subjects: 64
Study: 19019049

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (35 microg/hour) plus epidural morphine and ropivacaine (200 mg + 2 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epidural morphine and ropivacaine (200 mg + 2 mg) with placebo patch
Number of subjects: 86
Study: 17452486

Group type: EXPERIMENTAL
Intervention: Higher dose of rifampin (600 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dose of rifampin (450 mg)
Number of subjects: 50
Study: 14960009

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 921

Group type: COMPARATOR
Intervention: Brushing
Number of subjects: 921
Study: 10529580

Group type: EXPERIMENTAL
Intervention: Kneippism (custom‐tailored combination of therapies comprising hydrotherapy, kinesiotherapy, phytotherapy, dietetics, 'ordnungstherapie', and continued disease‐specific standard treatment)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Kneippism
Number of subjects: 363
Study: 8690110

Group type: EXPERIMENTAL
Intervention: Homogeneous endometrial pattern
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Trilaminar endometrial pattern
Number of subjects: 175
Study: 1755466

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactational amenorrhea method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total family planning coverage
Number of subjects: 0
Study: 6978270

Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin 100 mg daily
Number of subjects: 40
Study: 31896686

Group type: EXPERIMENTAL
Intervention: Chlorambucil or rituximab or chlorambucil plus rituximab (systemic treatment)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Systemic treatment (validation set)
Number of subjects: 688
Study: 31242926

Group type: EXPERIMENTAL
Intervention: Combined exercise intervention based on internet and social media software (CEIBISMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional treatment and rehabilitation
Number of subjects: 60
Study: 28323948

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg BID
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25960024

Group type: EXPERIMENTAL
Intervention: Low-pressure, knee-length graduated compression stockings
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Low-pressure, thigh-length graduated compression stockings
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Moderate-pressure, knee-length graduated compression stockings
Number of subjects: 219

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 219
Study: 22646157

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily (loading dose 300 mg) plus indobufen 100 mg twice a day (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily after 300 mg loading dose (group B)
Number of subjects: 42
Study: 21136226

Group type: EXPERIMENTAL
Intervention: Genetic causal information
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 110
Study: 19631119

Group type: EXPERIMENTAL
Intervention: Bilateral Zyoptix aspheric algorithm (aspheric group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Bilateral conventional Zyoptix Tissue Saving algorithm (control group)
Number of subjects: 170
Study: 17030113

Group type: EXPERIMENTAL
Intervention: Muscadine grape wine (MW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dealcoholized muscadine grape wine (Dz‐W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muscadine grape juice (MJ)
Number of subjects: 0